CLINICAL TRIALS PROFILE FOR GLUTAMINE
✉ Email this page to a colleague
All Clinical Trials for Glutamine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000925 ↗ | A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 1999-05-01 | The purpose of this study is to determine whether a high-quality protein food supplement will help HIV-positive patients maintain, and possibly gain, muscle mass. Many HIV-positive patients lose weight that they are then unable to regain. This may be because patients are not eating enough protein or are not eating the right kinds of protein. The protein eaten in foods (such as meat, eggs, or beans) may not be able to make up for the amount of protein lost due to HIV infection. This study gives patients high-quality protein food supplements to help them maintain and/or gain weight. |
| NCT00005775 ↗ | Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants | Completed | National Center for Research Resources (NCRR) | Phase 3 | 1999-07-01 | This large multicenter double-masked clinical trial tested whether supplementation of standard neonatal parenteral nutrition with glutamine would reduce the risk of death or late-onset sepsis in extremely-low-birth-weight (ELBW, less than or equal to 1000 gm) infants. Neonates with birth weights of 401-1000gm were randomized to standard TrophAmine or TrophAmine supplemented with glutamine before 72 hours and continued until the infants are tolerating full enteral feedings. |
| NCT00005775 ↗ | Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants | Completed | NICHD Neonatal Research Network | Phase 3 | 1999-07-01 | This large multicenter double-masked clinical trial tested whether supplementation of standard neonatal parenteral nutrition with glutamine would reduce the risk of death or late-onset sepsis in extremely-low-birth-weight (ELBW, less than or equal to 1000 gm) infants. Neonates with birth weights of 401-1000gm were randomized to standard TrophAmine or TrophAmine supplemented with glutamine before 72 hours and continued until the infants are tolerating full enteral feedings. |
| NCT00005889 ↗ | Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion | Unknown status | Baylor College of Medicine | N/A | 1999-10-01 | RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels. |
| NCT00005889 ↗ | Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion | Unknown status | National Center for Research Resources (NCRR) | N/A | 1999-10-01 | RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels. |
| NCT00006994 ↗ | S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat | Terminated | National Cancer Institute (NCI) | Phase 3 | 2001-11-01 | RATIONALE: Glutamine may be effective in decreasing side effects, such as inflammation of the mouth and throat, caused by radiation therapy. The effectiveness of glutamine for mucositis is not yet known. PURPOSE: Randomized phase III trial to determine the effectiveness of glutamine in treating patients who develop mucositis following radiation therapy for newly diagnosed cancer of the mouth or throat. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Glutamine
Condition Name
Clinical Trial Locations for Glutamine
Trials by Country
Clinical Trial Progress for Glutamine
Clinical Trial Phase
Clinical Trial Sponsors for Glutamine
Sponsor Name
